Research Article

Reconstruction Methods and Complications of Esophagastrostomy and Jejunal Interposition in Proximal Gastrectomy for Gastric Cancer: A Meta-Analysis

Nan Du, Pei Wu, Pengliang Wang, Yuwei Du, Kai Li, Zhenning Wang, Huimian Xu, and Zhi Zhu

Department of Surgical Oncology, Department of General Surgery, First Affiliated Hospital, China Medical University, Shenyang, China

Correspondence should be addressed to Zhi Zhu; zhuzhi@cmu.edu.cn

Received 14 September 2019; Revised 7 December 2019; Accepted 28 December 2019; Published 16 January 2020

Academic Editor: Vincenzo Pilone

Copyright © 2020 Nan Du et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Proximal gastrectomy is used for the treatment of primary gastric cancer by open or laparoscopic surgery in the upper third of the stomach. Esophagastrostomy (EG) or jejunal interposition (JI) is widely used in various reconstruction methods after proximal gastrectomy. We conducted a meta-analysis of EG and JI for treatment of gastric cancer.

Materials and Methods. A search of PubMed, Embase, MEDLINE, J-STAGE, and Cochrane Library identified retrospective series on EG and JI. Weight mean differences (WMDs), odds ratios (ORs), and 95% confidence intervals (CIs) were used to analyze the operation-related data and postoperative complications. Heterogeneity was evaluated by the I² test, and potential publication bias was assessed with Egger regression tests and sensitivity analysis.

Results. Eight studies were selected, and 496 patients were included. EG group benefits were 44.81 min shorter operating time (P < 0.001), 56.58 mL less blood loss (P = 0.03), and 7.4 days shorter hospital stay time (P < 0.001) than the JI group. Between the two groups, there was no significant difference in anastomotic leakage; otherwise, the EG group had a lower risk of anastomotic stenosis (OR = 0.44, 95%CI = 0.20 to 0.97, P = 0.04), lower risk of intestinal obstruction (OR = 0.07, 95%CI = 0.01 to 0.43, P = 0.004), and higher risk of reflux esophagitis (OR = 2.47, 95%CI = 1.07 to 5.72, P = 0.03).

Conclusion. The results of our study indicated that EG has significant advantages during the perioperative period and in short-term outcomes compared to JI.

1. Introduction

Proximal gastric cancer is characterized by large tumor size, high incidence of lymph node metastasis, strong invasive ability, and poor prognosis. The incidence of proximal gastric cancer has increased significantly in China in recent years [1]. Radical surgery is still the most effective cure, and the Japanese Gastric Carcinoma Association (JGCA) guidelines (14th edition) suggest that patients should accept D0, D1, and D1+ lymphadenectomy radical surgery, but the choice of reconstruction method is still a journal of concern issue. JGCA treatment guidelines indicate that proximal gastrectomy (PG) should only be performed for early gastric cancer, and at least half of the stomach should be preserved to maintain physiological function of the remnant stomach by open or laparoscopic surgery [2]. That could maintain the gastric reservoir with preservation of physiological function [3, 4] and improve postoperative quality of life [5]. There are various reconstruction methods after PG, such as esophagogastrostomy (EG), jejunal interposition (JI), jejunal pouch interposition (JPI), gastric tube reconstruction, and double tract (DT). EG has been widely used compared with the other reconstruction methods and is a simple and easy reconstruction method because it only has one anastomotic site [6].

JI reconstruction was first reported in 1946 and is associated with lower risk of reflux esophagitis [7]. Many authors stated that JI has significant short-term advantages. Katai et al. recommended that JI is an optimal treatment method with favorable long-term postoperative outcome [8]. Quite a few studies have reported that JI can reduce reflux...
esophagitis significantly and has diet tolerance with few complications [9].

EG and JI are used more frequently than other reconstruction methods. However, the standard method of reconstruction after PG is still controversial. Therefore, the purpose of this study was to compare the clinical efficacy of two reconstruction methods and to identify the advantages of EG and JI.

2. Materials and Methods

2.1. Study Selection. Search of Medline, Embase, J-STAGE, Cochrane Library, and PubMed databases identified retrospective series on EG and JI. We used the terms “gastrectomy,” “gastric cancer,” “esophagogastrectomy,” and “jejunal interposition” using [Mesh] or [free words]. The search was limited to January 1990 to January 2019.

2.2. Data Extraction. Two researchers (Nan D and Pei W) extracted the data independently. Final check was confirmed by the corresponding author. The data included the following parameters: operating time [10–14], blood loss [10–14], hospital stays [11–14], anastomotic leakage [11, 12, 14–17], anastomotic stenosis [11–17], intestinal obstruction [11, 12, 17], and reflux esophagitis [10–12, 14–17].

2.3. Inclusion Criteria. The following are the inclusion criteria: (1) diagnosis of the tumor as primary gastric cancer; (2) studies including clinical course such as operation-related data and complications; (3) studies including EG and JI; (4) availability of published data; (5) TNM stage lower than T3; and (6) adult population.

2.4. Exclusion Criteria. The following are the exclusion criteria: (1) gastric cancer was not the primary lesion; (2) case reports, letters, or meta-analyses; and (3) patients had severe underlying disease that may have affected treatment outcome.

2.5. Quality Assessment. Our meta-analysis included only retrospective cohort studies. Therefore, the Newcastle-Ottawa Scale (NOS) was used to analyze the quality of each study [18]. A cumulative score of NOS is according to three domains: the selection of study groups, comparability of cases, and ascertaining of the outcome. The scale of NOS is based on a 9-score model. Studies were considered having a high risk of bias (low quality) with scoring of less than three, medium risk of bias (moderate quality) if the score was four to six, and low risk of bias (high quality) if the score was seven to nine. Two researchers (Nan D and Pei W) assessed the trials independently. When opinions differed, the issue was resolved by the corresponding author.

2.6. Statistical Analysis. The data were analyzed using Review Manager Version 5.3 and Stata 11.0. Weight mean differences (WMDs), odds ratios (ORs), and 95% confidence intervals (CIs) were used to analyze the clinical outcomes and complications. Heterogeneity was measured with $I^2$ index and $P$ value [19]. Heterogeneity was regarded as significant with $I^2 > 50\%$ or $P$ value < 0.1. Due to inherent biases in retrospective study designs, the analyses were combined with the random-effects model. Potential publication bias was assessed with the Egger regression test. Sensitivity analysis was used to further assess the potential effect of heterogeneity by excluding one study at a time.

In this study, we followed the preferred reporting items, as stated in the systematic reviews and meta-analyses (PRISMA) [20].

3. Results

A total of 3,194 studies were reviewed in our search (see Figure 1), and 2,114 articles were excluded because they were not relevant. Finally, we included eight relevant articles [10–17] with a total of 496 patients. Depending on NOS criteria, three studies were retrospective with medium risk of bias and five studies were considered high quality with low risk of bias (see Table 1).

4. Operation-Related Data

4.1. Operating Time. Five articles had available data on operating time; four of which demonstrated that EG had a shorter operating time than JI had (WMD = -44.81, 95%CI = -70.46 to -19.16, $P < 0.001$). The heterogeneity between the groups was high in the random-effects model ($I^2 = 79\%$, $P < 0.001$) (see Figure 2(a)), which disappeared ($I^2 = 0$, $P = 0.40$) when Yasuda 2015 trial was excluded; the WMD ranged from -44.81 (95% CI -70.46 to -19.16) to -54.96 (95% CI -66.95 to -42.98). The Egger test showed that there was no publication bias ($P = 0.561$).
Table 1: Clinical characteristic of the included studies in meta-analysis.

| Authors          | Years | Design     | Quality score | Group | No. of patients | Age (mean) | Gender (M/F) | Population |
|------------------|-------|------------|---------------|-------|-----------------|------------|--------------|------------|
| Seike et al. [15]| 1998  | Retrospective | 5            | EG    | 11              | 69.3       | 10/1         | EGC        |
|                  |       |            |               | JI    | 14              | 54.8       |              | 8/6        |
| Ichikawa et al. [16] | 2001 | Retrospective | 5            | EG    | 13              | N/A        | N/A          | EGC        |
|                  |       |            |               | JI    | 13              | N/A        | N/A          | N/A        |
| Tokunaga et al. [10] | 2009 | Retrospective | 6            | EG    | 36              | 63.6       | 30/6         | EGC/AGC    |
|                  |       |            |               | JI    | 40              | 60.9       |              | 31/9       |
| Seshimo et al. [11] | 2013 | Retrospective | 7            | EG    | 46              | 64.8       | 36/10        | EGC/AGC    |
|                  |       |            |               | JI    | 18              | 68.0       |              | 13/5       |
| Yasuda et al. [12] | 2015 | Retrospective | 7            | EG    | 25              | 71.6       | 18/7         | EGC        |
|                  |       |            |               | JI    | 21              | 61.0       |              | 13/8       |
| Masuzawa et al. [13] | 2014 | Retrospective | 9            | EG    | 49              | 64.0       | 36/13        | EGC        |
|                  |       |            |               | JI    | 32              | 65.0       |              | 25/7       |
| Isobe et al. [14] | 2014  | Retrospective | 8            | EG    | 66              | 71.6       | 52/14        | EGC/AGC    |
|                  |       |            |               | JI    | 23              | 59.4       |              | 18/5       |
| Nakamura et al. [17] | 2014 | Retrospective | 8            | EG    | 64              | 73         | 49/15        | EGC        |
|                  |       |            |               | JI    | 25              | 70         |              | 21/4       |

(a) Operating time

| Study or subgroup | Mean   | SD     | Total | Mean   | SD     | Total | Weight | Mean difference IV, random, 95% CI |
|-------------------|--------|--------|-------|--------|--------|-------|--------|-----------------------------------|
| Isobe 2014        | 199    | 43.1   | 66    | 251.7  | 43.6   | 23    | 22.2%  | −52.70 [−73.33, −32.07]           |
| Masuzawa 2014     | 185    | 48     | 49    | 230.4  | 43     | 32    | 22.3%  | −45.00 [−65.06, −24.94]           |
| Seshimo 2013      | 217    | 50     | 46    | 294.6  | 68     | 18    | 17.6%  | −77.00 [−111.58, −42.42]          |
| Tokunaga 2009     | 203    | 55.5   | 38    | 267.3  | 73.8   | 45    | 19.8%  | −64.00 [−91.86, −36.14]           |
| Yasuda 2015       | 286.4  | 286.4  | 25    | 268.8  | 59.6   | 21    | 18.1%  | 17.60 [−15.61, 50.81]             |
| Total             | 224    |        |       | 139    |        |       | 100.0% | −44.81 [−70.46, −19.16]          |

(b) Blood loss

| Study or subgroup | Mean   | SD     | Total | Mean   | SD     | Total | Weight | Mean difference IV, random, 95% CI |
|-------------------|--------|--------|-------|--------|--------|-------|--------|-----------------------------------|
| Isobe 2014        | 176.5  | 144.2  | 66    | 230.4  | 182   | 32    | 29.9%  | −51.00 [−144.33, 36.63]           |
| Masuzawa 2014     | 280    | 247    | 49    | 331    | 182   | 32    | 29.9%  | −51.00 [−144.33, 36.63]           |
| Seshimo 2013      | 253    | 246    | 46    | 413    | 312   | 18    | 10.1%  | −160.00 [−320.71, 0.71]           |
| Tokunaga 2009     | 252    | 308.2  | 38    | 287    | 214.7 | 45    | 19.3%  | −35.00 [−151.35, 81.35]           |
| Yasuda 2015       | 294.2  | 334.5  | 25    | 307.4  | 264.8 | 21    | 8.7%   | −13.20 [−186.46, 160.06]          |
| Total             | 224    |        |       | 139    |        |       | 100.0% | −56.58 [−107.74, −5.42]          |

(c) Hospital stays

| Study or subgroup | Mean   | SD     | Total | Mean   | SD     | Total | Weight | Mean difference IV, random, 95% CI |
|-------------------|--------|--------|-------|--------|--------|-------|--------|-----------------------------------|
| Isobe 2014        | 15.6   | 10.4   | 66    | 24.1   | 17.7   | 23    | 14.6%  | −8.50 [−16.16, −0.84]             |
| Masuzawa 2014     | 20     | 17     | 49    | 23     | 31     | 32    | 6.2%   | −3.00 [−14.75, 8.75]              |
| Seshimo 2013      | 19     | 5      | 46    | 26     | 7      | 18    | 68.1%  | −7.00 [−10.54, −3.46]             |
| Yasuda 2015       | 18.6   | 5.6    | 25    | 29.4   | 19.8   | 21    | 11.2%  | −10.80 [−19.55, −2.05]            |
| Total             | 186    |        |       | 94     |        |       | 100.0% | −7.40 [−10.32, −4.47]             |

Figure 2: Meta-analysis of operative data on EG versus JI: (a) operative time (min), (b) blood loss (mL), and (c) postoperative hospital stays (days).
4.2. Blood Loss. Five articles were used to compare blood loss between the groups. The JI and EG groups had a significant decrease in blood loss in the random-effects model (WMD = −56.38, 95% CI = -107.74 to -5.42, P = 0.03). There was no heterogeneity (I² = 0%, P = 0.74) (see Figure 2(b)). Sensitivity analyses showed no changing of heterogeneity by omitting one study at a time. The Egger test showed that there was no obvious potential publication bias (P = 0.655).

4.3. Hospital Stays. Five studies reported hospital stay. There was no significant heterogeneity between the groups (I² = 0%, P = 0.74). In the EG group, hospital stay was 7.4 days shorter than in the JI group in the random-effects model (WMD = -7.40, 95% CI = -10.32 to -4.47, P < 0.001) (see Figure 2(c)). Sensitivity analysis manifested no significant heterogeneity change. The Egger test showed no evidence of publication bias (P = 0.157).

5. Complications

5.1. Anastomotic Leakage. Six articles reported anastomotic leakage, but there was no significant difference between the two groups in the random-effects model (OR = 0.42, 95% CI = 0.10 to 1.72, P = 0.23) with low heterogeneity (I² = 26%, P = 0.24) (see Figure 3(a)). Sensitivity analysis showed no heterogeneity changing. There was no significant publication bias (P = 0.383).

5.2. Anastomotic Stenosis. Seven articles reported anastomotic stenosis. The incidence of anastomotic stenosis in the JI group was higher than that in the EG group in the random-effects model (OR = 0.44, 95% CI = 0.20 to 0.97, P = 0.04). There was no heterogeneity (I² = 0%, P = 0.52) (see Figure 3(b)) and no publication bias between the two groups (P = 0.460). Sensitivity analysis for this parameter showed no significant change when a single study was removed.

5.3. Intestinal Obstruction. Three articles included data on intestinal obstruction. The JI group had a significant 91% increase in the risk of intestinal obstruction in the random-effects model (OR = 0.07, 95% CI = 0.01 to 0.43, P = 0.004), and no heterogeneity was present (I² = 0%, P = 1.00) (see Figure 3(c)). Sensitivity analysis demonstrated no heterogeneity changing. The studies to assess the publication bias were not enough.
showed that the overall efficacy was higher in the EG group compared with the JI group (OR = 2.47, 95% CI = 1.07 to 5.72, P = 0.03). Among the trials, there was no heterogeneity (I² = 0, P = 0.64) (see Figure 4) or publication bias (P = 0.093). Sensitivity analyses showed that the overall effects remained similar by excluding the trials by turns.

6. Discussion

PG has been used worldwide, and postoperative reconstruction methods are controversial. The JGCA recommends that different reconstruction methods are controversial. The JGCA recommends that JI is a superior reconstruction method compared with EG [23]. It remains unclear as to which type of reconstruction is most effective after PG.

We performed a meta-analysis to compare the postoperative complications between EG and JI. Compared to JI, in the EG group, operating time and hospital stay were shorter and there was less blood loss. Furthermore, EG also had the advantage of technical simplicity, which reduced surgical difficulty and increased patient safety. The EG group had a lower risk of anastomotic stenosis and intestinal obstruction compared with the JI group, but the EG group had a higher risk of postoperative reflux esophagitis. We demonstrated that EG had significant short-term efficacy.

EG is related to the high postoperative risk of reflux esophagitis, and it has been shown that gastroesophageal reflux is associated with lower morbidity [27]. In particular, Nissen fundoplication can be regarded as a safe and effective treatment method with low morbidity [27]. In our study, only one study used a laparoscopic-assisted technique. This simple procedure combines a gastric tube with the angle of His, which can preserve the quality of life. Laparoscopic gastrectomy carries a lower risk of inflammatory reactions in Asian gastric cancer patients [31]. Although laparoscopy-assisted PG has advantages in short-term outcomes for early gastric cancer, the results should be confirmed by more clinical trials.

D2 total gastrectomy has been considered the standard procedure for the treatment of gastric cancer worldwide. In recent decades, PG has frequently been performed in China and Japan to preserve the physiological function for maintaining the gastric reservoir for early proximal gastric cancer. Some authors advocated functional advantages of PG with JI over total gastrectomy with Roux-en-Y EG [32]. By contrast, in western countries, no consensus has been reached on the reconstruction of proximal gastric cancer. Rosa et al. claimed that PG might increase the mortality rate and risks of complications [33]. PG has been performed in patients with advanced gastric cancer, although some still prefer total gastrectomy. In previous retrospective studies, many clinical parameters, such as cancer stage, body mass index, surgical outcome, and frequent postoperative complications, were not included, and these issues need to be considered.

| Study or subgroup | EG Events | Total | JI Events | Total | Weight | M--H, random, 95% CI | Odds ratio M--H, random, 95% CI |
|-------------------|-----------|-------|-----------|-------|--------|----------------------|--------------------------------|
| Ichikawa 2001     | 3         | 13    | 2         | 13    | 17.9%  | 1.65 [0.23, 11.99]   |                                |
| Isobe 2014        | 2         | 66    | 0         | 23    | 7.4%   | 1.82 [0.08, 39.36]   |                                |
| Kamihoro 1998     | 4         | 10    | 0         | 14    | 7.5%   | 20.08 [0.94, 430.22] |                                |
| Nakamura 2014     | 12        | 55    | 0         | 22    | 8.5%   | 12.93 [0.73, 228.56] |                                |
| Seshimo 2013      | 10        | 46    | 2         | 18    | 26.5%  | 2.22 [0.44, 11.32]   |                                |
| Tokunaga 2009     | 3         | 38    | 3         | 45    | 25.5%  | 1.20 [0.23, 6.32]    |                                |
| Yasuda 2015       | 1         | 25    | 0         | 23    | 6.7%   | 2.88 [0.11, 74.23]   |                                |
| Total (95% CI)    | 253       | 158   | 100.0%    |       | 2.47 [1.07, 5.72]    |                                |
| Total events      | 35        | 7     | 100.0%    |       |         |                      |                                |
| Heterogeneity: tau² = 0.00; chi² = 4.26, df = 6 (P = 0.64); I² = 0% | |
| Test for overall effect: Z = 2.12 (P = 0.03) | |
At present, there are several methods of reconstruction of the alimentary tract after PG. In addition to EG and JI, there are many other reconstruction methods like JPI and DT. A multitude of studies has reported that JPI is comparatively easy and can improve the postoperative quality of life compared to single JI [23, 34, 35]. Nakamura et al. clarified that, in comparison to JI and JPI, EG had benefits of lower invasiveness. Additionally, a host of studies have suggested that DT reconstruction has a lower incidence of postoperative complications than EG has especially reflux esophagitis [36, 37]. However, its superiority needs more long-term clinical data to confirm.

The limitations of the present study were as follows. First, the heterogeneity of operating time was significant ($I^2 = 79\%$). That might have been the result of different surgical techniques of the surgeons and different surgical equipment of the hospital. We conducted a sensitivity analysis to assess the potential effect of heterogeneity of operating time and found the Yasuda 2015 trial could be the major originator after excluded (the $I^2$ ranged from 79% to 0). We further compared the Yasuda 2015 trial with extra included trials. We found that the surgical technique of the EG group was modified by creating the new cardiac notch (angle of His). This complex procedure might need more operating time to finalize, and it could be one of the main reasons for high heterogeneity. Second, the trials included in our study all had short-term outcomes, and long-term overall survival is still controversial. Third, on account of not enough studies, we could not assess the evidence of publication bias on the trials of intestinal obstruction. Furthermore, we used the random-effects model to replace the fixed-effects model when the heterogeneity was significant. Moreover, our meta-analysis only included EG and JI, and there are many other types of reconstruction; however, there is no comprehensive study to clarify the optimal reconstructive procedure after PG.

7. Conclusions

In conclusion, our study indicated that EG had significant advantages during the perioperative period and for short-term outcomes compared to JI. Moreover, EG combined with fundoplication reduced the risk of complications and improved the quality of life. However, the overall survival and long-term prognosis after PG should be confirmed by large multicenter clinical trials with longer follow-up.

Data Availability

The data supporting this meta-analysis are from previously reported studies and datasets, which have been cited. The processed data are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

ZZ contributed to the conception and design of the study and drafted the manuscript. ND, PW, and YD contributed to the analysis and interpretation of data and revised the manuscript. ND, KL, and ZW participated in the data acquisition and literature research. All authors read and approved the final manuscript.

Supplementary Materials

Table S1: risk of bias assessment in those 8 observational studies. Figure S1: Egger’s publication bias plot of operating time. Figure S2: Egger’s publication bias plot of blood loss. Figure S3: Egger’s publication bias plot of hospital stays. Figure S4: Egger’s publication bias plot of anastomotic leakage. Figure S5: Egger’s publication bias plot of anastomotic stenosis. Figure S6: Egger’s publication bias plot of reflux esophagitis. Figure S7: age moderator metaregression analyses for reflux esophagitis in EG vs. JI. Figure S8: gender moderator metaregression analyses for reflux esophagitis in EG vs. JI. (Supplementary Materials)

References

[1] J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.

[2] Japanese Gastric Cancer Association, “Japanese gastric cancer treatment guidelines 2014 (ver. 4),” Gastric Cancer, vol. 20, no. 1, pp. 1–19, 2017.

[3] K. Hosoda, K. Yamashita, H. Moriya et al., “Laparoscopically assisted proximal gastrectomy with esophagogastrectomy using a novel “open-door” technique: LAGP with novel reconstruction,” Journal of Gastrointestinal Surgery, vol. 21, no. 7, pp. 1174–1180, 2017.

[4] N. Shiraishi, Y. Adachi, S. Kitano, K. Kakisako, M. Inomata, and K. Yasuda, “Clinical outcome of proximal versus total gastrectomy for proximal gastric cancer,” World Journal of Surgery, vol. 26, no. 9, pp. 1150–1154, 2002.

[5] Y. Kitagawa, S. Kitano, T. Kubota et al., “Minimally invasive surgery for gastric cancer—toward a confluence of two major streams: a review,” Gastric Cancer, vol. 8, no. 2, pp. 103–110, 2005.

[6] M. Nakamura and H. Yamaue, “Reconstruction after proximal gastrectomy for gastric cancer in the upper third of the stomach: a review of the literature published from 2000 to 2014,” Surgery Today, vol. 46, no. 5, pp. 517–527, 2016.

[7] C. P. Hsu, C. Y. Chen, Y. H. Hsieh, J. Y. Hsia, S. E. Shai, and C. H. Kao, “Esophageal reflux after total or proximal gastrectomy in patients with adenocarcinoma of the gastric cardia,” The American Journal of Gastroenterology, vol. 92, no. 8, pp. 1347–1350, 1997.

[8] H. Katai, S. Morita, M. Saka, H. Taniguchi, and T. Fukagawa, “Long-term outcome after proximal gastrectomy with jejunal interposition for suspected early cancer in the upper third of the stomach,” The British Journal of Surgery, vol. 97, no. 4, pp. 558–562, 2010.

[9] H. Katai, T. Sano, T. Fukagawa, H. Shinohara, and M. Sasako, “Prospective study of proximal gastrectomy for early gastric cancer.”
cancer in the upper third of the stomach,” *The British Journal of Surgery*, vol. 90, no. 7, pp. 850–853, 2003.

[10] M. Tokunaga, N. Hiki, S. Ohyama et al., “Effects of reconstruction methods on a patient’s quality of life after a proximal gastrectomy: subjective symptoms evaluation using questionnaire survey,” *Langenbeck’s Archives of Surgery*, vol. 394, no. 4, pp. 637–641, 2009.

[11] A. Seshimo, K. Miyake, K. Amano, K. Aratake, and A. Yasuda, T. Yasuda, H. Imamoto et al., “A newly modified esophagogastrostomy with a reliable angle of His by placing a gastric tube in the lower mediastinum in laparoscopy-assisted proximal gastrectomy,” *Gastric Cancer*, vol. 18, no. 4, pp. 850–858, 2015.

[12] T. Masuzawa, S. Takiguchi, M. Hirao et al., “Comparison of perioperative and long-term outcomes of total and proximal gastrectomy for early gastric cancer: a multi-institutional retrospective study,” *World Journal of Surgery*, vol. 38, no. 5, pp. 1100–1106, 2014.

[13] T. Isobe, K. Hashimoto, J. Kizaki et al., “Reconstruction methods and complications in proximal gastrectomy for gastric cancer, and a comparison with total gastrectomy,” *The Kurume Medical Journal*, vol. 61, no. 1, pp. 23–29, 2014.

[14] K. Seike, T. Kinoshita, M. Sugito et al., “Comparative studies between esophagogastrostomy and jejunal Interposition after proximal gastrectomy for cardiac cancer of the stomach,” *The Japanese Journal of Gastroenterological Surgery*, vol. 31, no. 4, pp. 900–907, 1998.

[15] D. Ichikawa, Y. Ueshima, K. Shirone et al., “Esophagogastrostomy reconstruction after limited proximal gastrectomy,” *Hepatogastroenterology*, vol. 48, no. 42, pp. 1797–1801, 2001.

[16] M. Nakamura, M. Nakamori, T. Ojima et al., “Reconstruction after proximal gastrectomy for early gastric cancer in the upper third of the stomach: an analysis of our 13-year experience,” *Surgery*, vol. 156, no. 1, pp. 57–63, 2014.

[17] S. Y. Kim, J. E. Park, Y. J. Lee et al., “Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity,” *Journal of Clinical Epidemiology*, vol. 66, no. 4, pp. 408–414, 2013.

[18] J. P. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” *BMJ*, vol. 327, no. 7414, pp. 557–560, 2003.

[19] L. A. Stewart, M. Clarke, M. Rovers et al., “Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data,” *Journal of the American Medical Association*, vol. 313, no. 16, pp. 1657–1665, 2015.

[20] J. A. Ajani, T. A. D’Amico, K. Almhanna et al., “Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology,” *Journal of the National Comprehensive Cancer Network*, vol. 14, no. 10, pp. 1286–1312, 2016.

[21] H. Tsuji, S. Ando, and A. Mitsui, “Evaluation of postoperative quality of life of proximal gastrectomy preserving anti-reflux function in lower esophagus for gastric tumor,” *The Japanese Journal of Gastroenterological Surgery*, vol. 38, no. 4, pp. 377–384, 2005.

[22] H. Kameyama, A. Nashimoto, H. Yabusaki, Y. Tsuchiya, Y. Takii, and O. Tanaka, “Reconstruction after proximal gastrectomy: comparison with single loop jejunal interposition and jejunal pouch interposition,” *Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)*, vol. 65, no. 9, pp. 2294–2298, 2004.

[23] H. Ishii, E. Bando, K. Morimoto, N. Kojima, T. Kawamura, and Y. Yonemura, “A case of intractable reflux esophagitis post proximal gastrectomy for which lower esophagectomy and remnant gastrectomy proved effective,” *Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)*, vol. 67, no. 9, pp. 2057–2060, 2006.

[24] J. A. Ajani, T. Inoue, Y. Hagino, N. Shiraishi, K. Shimoda, and S. Kitano, “Surgical results of proximal gastrectomy for early-stage gastric cancer: jejunal interposition and gastric tube reconstruction,” *Gastric Cancer*, vol. 2, no. 1, pp. 40–45, 1999.

[25] S. Someya, C. Shibata, N. Tanaka et al., “Duodenal switch for intractable reflux gastroesphagitis after proximal gastrectomy,” *The Tohoku Journal of Experimental Medicine*, vol. 230, no. 3, pp. 129–132, 2013.

[26] A. L. Shada, C. M. Dunst, R. Pescarus et al., “Laparoscopic pyloroplasty is a safe and effective first-line surgical therapy for refractory gastroparesis,” *Surgical Endoscopy*, vol. 30, no. 4, pp. 1326–1332, 2016.

[27] K. Sakai, T. Furukawa, O. Kimura et al., “Comparison of outcomes of anterior wrapping and posterior wrapping in laparoscopic fundoplication,” *Japanese Society of Pediatric Surgeons*, vol. 52, pp. 78–82, 2016.

[28] C. D. Zhang, H. Yamashita, S. Zhang, and Y. Seto, “Reevaluation of laparoscopic versus open distal gastrectomy for early gastric cancer in Asia: a meta-analysis of randomized controlled trials,” *International Journal of Surgery*, vol. 56, pp. 31–43, 2018.

[29] Y. Deng, Y. Zhang, and T. K. Guo, “Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: a meta-analysis based on seven randomized controlled trials,” *Surgical Oncology*, vol. 24, no. 2, pp. 71–77, 2015.

[30] Z. B. Shu, H. P. Cao, Y. C. Li, and L. B. Sun, “Infuences of laparoscopic-assisted gastrectomy and open gastrectomy on serum interleukin-6 levels in patients with gastric cancer among Asian populations: a systematic review,” *BMC Gastroenterology*, vol. 15, no. 1, p. 52, 2015.

[31] M. Ohashi, S. Morita, T. Fukagawa, I. Oda, R. Kushima, and H. Katai, “Functional advantages of proximal gastrectomy with jejunal interposition over total gastrectomy with Roux-en-Y esophagogastrostomy for early gastric cancer,” *World Journal of Surgery*, vol. 39, no. 11, pp. 2726–2733, 2015.

[32] F. Rosa, G. Quero, C. Fiorillo et al., “Total vs proximal gastrectomy for adenocarcinoma of the upper third of the stomach: a propensity-score-matched analysis of a multicenter western experience (on behalf of the Italian Research Group for Gastric Cancer–GIRCG),” *Gastric Cancer*, vol. 21, no. 5, pp. 845–852, 2018.

[33] T. Iwata, N. Kurita, T. Ikemoto, M. Nishioka, T. Andoh, and M. Shimada, “Evaluation of reconstruction after proximal gastrectomy: prospective comparative study of jejunal interposition and jejunal pouch interposition,” *Hepatogastroenterology*, vol. 53, no. 68, pp. 301–303, 2006.

[34] N. Senmaru, T. Morita, Y. M. Yonemura, and H. Katai, “Comparison of jejunal interposition and jejunal pouch interposition after proximal gastrectomy,” *The Japanese Journal of Gastroenterological Surgery*, vol. 32, no. 10, pp. 2309–2313, 1999.
[36] T. Aburatani, K. Kojima, S. Otsuki et al., "Double-tract reconstruction after laparoscopic proximal gastrectomy using detachable ENDO-PSD," Surgical Endoscopy, vol. 31, no. 11, pp. 4848–4856, 2017.

[37] S. H. Ahn, D. H. Jung, S. Y. Son, C. M. Lee, D. J. Park, and H. H. Kim, "Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer," Gastric Cancer, vol. 17, no. 3, pp. 562–570, 2014.